Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

Next Previous
X
Search
Trial Profile

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belantamab mafodotin (Primary) ; Belumosudil (Primary) ; Dexamethasone (Primary) ; Evorpacept (Primary) ; Isatuximab (Primary) ; Pegenzileukin (Primary) ; SAR 439459 (Primary) ; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms UMBRELLA
  • Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

    • Most Recent Events

    • 04 Sep 2024 According to ALX Oncology Media Release, first patients has been dosed in this trial.
    • 05 Jul 2024 Planned End Date changed from 2 Mar 2028 to 31 Mar 2028.
    • 05 Jul 2024 Planned primary completion date changed from 30 Jun 2027 to 28 Jul 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top